vs
Broadridge Financial Solutions（BR）与Encompass Health Corp（EHC）财务数据对比。点击上方公司名可切换其他公司
Broadridge Financial Solutions的季度营收约是Encompass Health Corp的1.1倍（$1.7B vs $1.5B），Broadridge Financial Solutions净利率更高（16.6% vs 9.5%，领先7.1%），Encompass Health Corp同比增速更快（9.9% vs -5.4%），过去两年Broadridge Financial Solutions的营收复合增速更高（10.4% vs 8.3%）
Broadridge Financial Solutions是2007年从自动数据处理公司（ADP）分拆成立的上市企业服务及金融科技企业，总部位于纽约莱克萨克塞斯，为金融行业客户提供股东委托书、年报等金融单证服务，以及线上年会等股东沟通解决方案。
Encompass Health Corp前身为Amcare及HealthSouth，总部位于美国阿拉巴马州伯明翰，是美国规模最大的住院康复服务提供商，在39个州及波多黎各拥有173家住院康复医院，为中风、神经系统疾病、心肺病症、脑损伤等患者提供专业康复诊疗服务。
BR vs EHC — 直观对比
营收规模更大
BR
是对方的1.1倍
$1.5B
营收增速更快
EHC
高出15.3%
-5.4%
净利率更高
BR
高出7.1%
9.5%
两年增速更快
BR
近两年复合增速
8.3%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.7B | $1.5B |
| 净利润 | $284.6M | $146.1M |
| 毛利率 | 27.6% | — |
| 营业利润率 | 12.0% | 16.7% |
| 净利率 | 16.6% | 9.5% |
| 营收同比 | -5.4% | 9.9% |
| 净利润同比 | 17.1% | 20.8% |
| 每股收益（稀释后） | $2.42 | $1.43 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BREHC
| Q4 25 | $1.7B | $1.5B | ||
| Q3 25 | — | $1.5B | ||
| Q2 25 | $2.1B | $1.5B | ||
| Q1 25 | $1.8B | $1.5B | ||
| Q4 24 | $1.6B | $1.4B | ||
| Q3 24 | $1.4B | $1.4B | ||
| Q2 24 | $1.9B | $1.3B | ||
| Q1 24 | $1.7B | $1.3B |
净利润BREHC
| Q4 25 | $284.6M | $146.1M | ||
| Q3 25 | — | $126.5M | ||
| Q2 25 | $374.2M | $142.1M | ||
| Q1 25 | $243.1M | $151.5M | ||
| Q4 24 | $142.4M | $120.9M | ||
| Q3 24 | $79.8M | $108.2M | ||
| Q2 24 | $323.2M | $114.1M | ||
| Q1 24 | $213.7M | $112.5M |
毛利率BREHC
| Q4 25 | 27.6% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 37.3% | — | ||
| Q1 25 | 31.8% | — | ||
| Q4 24 | 27.9% | — | ||
| Q3 24 | 24.5% | — | ||
| Q2 24 | 35.5% | — | ||
| Q1 24 | 31.2% | — |
营业利润率BREHC
| Q4 25 | 12.0% | 16.7% | ||
| Q3 25 | — | 14.9% | ||
| Q2 25 | 24.1% | 16.2% | ||
| Q1 25 | 19.0% | 16.4% | ||
| Q4 24 | 13.3% | 14.3% | ||
| Q3 24 | 9.4% | 13.6% | ||
| Q2 24 | 22.7% | 14.3% | ||
| Q1 24 | 17.5% | 13.6% |
净利率BREHC
| Q4 25 | 16.6% | 9.5% | ||
| Q3 25 | — | 8.6% | ||
| Q2 25 | 18.1% | 9.7% | ||
| Q1 25 | 13.4% | 10.4% | ||
| Q4 24 | 9.0% | 8.6% | ||
| Q3 24 | 5.6% | 8.0% | ||
| Q2 24 | 16.6% | 8.8% | ||
| Q1 24 | 12.4% | 8.5% |
每股收益（稀释后）BREHC
| Q4 25 | $2.42 | $1.43 | ||
| Q3 25 | — | $1.24 | ||
| Q2 25 | $3.17 | $1.39 | ||
| Q1 25 | $2.05 | $1.48 | ||
| Q4 24 | $1.20 | $1.18 | ||
| Q3 24 | $0.68 | $1.06 | ||
| Q2 24 | $2.72 | $1.12 | ||
| Q1 24 | $1.79 | $1.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $371.5M | $72.2M |
| 总债务越低越好 | $3.2B | $2.4B |
| 股东权益账面价值 | $2.9B | $2.4B |
| 总资产 | $8.6B | $7.1B |
| 负债/权益比越低杠杆越低 | 1.10× | 1.00× |
8季度趋势，按日历期对齐
现金及短期投资BREHC
| Q4 25 | $371.5M | $72.2M | ||
| Q3 25 | — | $48.7M | ||
| Q2 25 | $562.2M | $99.1M | ||
| Q1 25 | $317.9M | $95.8M | ||
| Q4 24 | $290.6M | $85.4M | ||
| Q3 24 | $293.5M | $147.8M | ||
| Q2 24 | $305.2M | $154.4M | ||
| Q1 24 | $236.4M | $134.4M |
总债务BREHC
| Q4 25 | $3.2B | $2.4B | ||
| Q3 25 | — | $2.4B | ||
| Q2 25 | $3.3B | $2.3B | ||
| Q1 25 | $3.4B | $2.3B | ||
| Q4 24 | $3.7B | $2.4B | ||
| Q3 24 | $3.6B | $2.3B | ||
| Q2 24 | $3.4B | $2.7B | ||
| Q1 24 | $3.5B | $2.7B |
股东权益BREHC
| Q4 25 | $2.9B | $2.4B | ||
| Q3 25 | — | $2.4B | ||
| Q2 25 | $2.7B | $2.3B | ||
| Q1 25 | $2.4B | $2.2B | ||
| Q4 24 | $2.2B | $2.1B | ||
| Q3 24 | $2.2B | $2.0B | ||
| Q2 24 | $2.2B | $1.8B | ||
| Q1 24 | $2.3B | $1.7B |
总资产BREHC
| Q4 25 | $8.6B | $7.1B | ||
| Q3 25 | — | $6.9B | ||
| Q2 25 | $8.5B | $6.8B | ||
| Q1 25 | $8.3B | $6.6B | ||
| Q4 24 | $8.2B | $6.5B | ||
| Q3 24 | $8.0B | $6.5B | ||
| Q2 24 | $8.2B | $6.4B | ||
| Q1 24 | $8.2B | $6.2B |
负债/权益比BREHC
| Q4 25 | 1.10× | 1.00× | ||
| Q3 25 | — | 1.01× | ||
| Q2 25 | 1.22× | 1.02× | ||
| Q1 25 | 1.44× | 1.08× | ||
| Q4 24 | 1.64× | 1.14× | ||
| Q3 24 | 1.63× | 1.20× | ||
| Q2 24 | 1.55× | 1.46× | ||
| Q1 24 | 1.55× | 1.54× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $346.0M |
| 自由现金流经营现金流 - 资本支出 | — | $116.7M |
| 自由现金流率自由现金流/营收 | — | 7.6% |
| 资本支出强度资本支出/营收 | — | 14.8% |
| 现金转化率经营现金流/净利润 | — | 2.37× |
| 过去12个月自由现金流最近4个季度 | — | $439.2M |
8季度趋势，按日历期对齐
经营现金流BREHC
| Q4 25 | — | $346.0M | ||
| Q3 25 | — | $270.8M | ||
| Q2 25 | $699.7M | $270.2M | ||
| Q1 25 | $360.4M | $288.6M | ||
| Q4 24 | $236.7M | $278.8M | ||
| Q3 24 | $-125.5M | $267.8M | ||
| Q2 24 | $721.0M | $217.4M | ||
| Q1 24 | $207.4M | $238.8M |
自由现金流BREHC
| Q4 25 | — | $116.7M | ||
| Q3 25 | — | $83.7M | ||
| Q2 25 | $684.1M | $113.3M | ||
| Q1 25 | $348.9M | $125.5M | ||
| Q4 24 | $227.9M | $80.1M | ||
| Q3 24 | $-133.4M | $120.3M | ||
| Q2 24 | $703.2M | $60.5M | ||
| Q1 24 | $184.6M | $99.4M |
自由现金流率BREHC
| Q4 25 | — | 7.6% | ||
| Q3 25 | — | 5.7% | ||
| Q2 25 | 33.1% | 7.8% | ||
| Q1 25 | 19.3% | 8.6% | ||
| Q4 24 | 14.3% | 5.7% | ||
| Q3 24 | -9.4% | 8.9% | ||
| Q2 24 | 36.2% | 4.6% | ||
| Q1 24 | 10.7% | 7.6% |
资本支出强度BREHC
| Q4 25 | — | 14.8% | ||
| Q3 25 | — | 12.7% | ||
| Q2 25 | 0.8% | 10.8% | ||
| Q1 25 | 0.6% | 11.2% | ||
| Q4 24 | 0.6% | 14.1% | ||
| Q3 24 | 0.6% | 10.9% | ||
| Q2 24 | 0.9% | 12.1% | ||
| Q1 24 | 1.3% | 10.6% |
现金转化率BREHC
| Q4 25 | — | 2.37× | ||
| Q3 25 | — | 2.14× | ||
| Q2 25 | 1.87× | 1.90× | ||
| Q1 25 | 1.48× | 1.90× | ||
| Q4 24 | 1.66× | 2.31× | ||
| Q3 24 | -1.57× | 2.48× | ||
| Q2 24 | 2.23× | 1.91× | ||
| Q1 24 | 0.97× | 2.12× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BR
| Recurring Fee Revenue Investor Communication Solutions | $589.5M | 34% |
| Recurring Fee Revenue Capital Markets | $300.9M | 18% |
| Recurring Fee Revenue Regulatory | $248.7M | 15% |
| Recurring Fee Revenue Customer Communications | $189.2M | 11% |
| Recurring Fee Revenue Wealth And Investment Management | $179.7M | 10% |
| Recurring Fee Revenue Data Driven Fund Solutions | $112.7M | 7% |
| Event Driven Revenue Mutual Funds | $51.4M | 3% |
| Event Driven Revenue Equity And Other | $39.2M | 2% |
| Global Technology And Operations | $7.5M | 0% |
EHC
| Medicare | $1.0B | 66% |
| Medicare Advantage | $243.1M | 16% |
| Managed Care | $160.7M | 10% |
| Medicaid | $47.0M | 3% |
| Other Income Source | $44.8M | 3% |
| Other Thirdparty Payors | $11.2M | 1% |
| Workers Compensation | $7.6M | 0% |
| Patients | $4.6M | 0% |
